Journal of cardiovascular development and disease · 2026
Multimodal Management of Chronic Thromboembolic Pulmonary Hypertension: A Narrative Review of Treatment Selection and Sequencing.
СтатьяОбзорНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Gharsalli Houda, Alshahrani Mohammed, Harbi Olfa, Alwadai Nawal, Al-Asiri Abdalla M, Alahmari Fatmah, Alqahtani Amal, Al-Jahash Najla, Abbag Lobna, Alqahtani Saud, Amer Khaled Abdulwahab
Аннотация
Chronic thromboembolic pulmonary hypertension (CTEPH) is a treatable yet frequently underdiagnosed late complication of acute pulmonary embolism, in which incompletely resolved thromboemboli organise into fibrotic obstructions of the pulmonary arteries and, together with a secondary small-vessel arteriopathy affecting both obstructed and non-obstructed territories, raise pulmonary vascular resistance, impose right ventricular pressure overload, and-if left untreated-progress to right heart failure and death. Three established therapies address the disease at distinct anatomical levels: pulmonary endarterectomy, the potentially curative treatment of choice for surgically accessible disease; balloon pulmonary angioplasty, for distal inoperable lesions or residual disease; and pulmonary hypertension-targeted medical therapy, for the accompanying microvasculopathy. Their evaluation in randomised controlled trials and large registries has produced a multimodal paradigm in which these treatments are combined and sequenced according to operability and lesion distribution. This narrative review synthesises evidence published through January 2026 to accomplish the following: (i) summarise and critically appraise the contemporary evidence for each modality, distinguishing guideline-supported recommendations from observational, proof-of-concept, and expert-opinion-based practice; (ii) describe how treatments are selected, sequenced, and bridged in relation to operability and to residual or recurrent pulmonary hypertension after endarterectomy; and (iii) situate treatment within the broader chronic thromboembolic pulmonary disease spectrum and the case-finding pathway after pulmonary embolism. Rather than proposing a validated algorithm, it emphasises that, because each modality carries distinct indications and risks, decisions should be individualised through multidisciplinary assessment at expert centres, with early referral central to optimising outcomes.